Imperial Innovations

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Imperial Innovations is a British technology transfer and commercialisation company. The company was founded in 1986 and its ordinary shares admitted to trading on the Alternative Investment Market of London Stock Exchange plc in July 2006, raising £25 million at an offer price of 365p and £1 million by means of a public offer.

The company’s integrated approach encompasses the identification of ideas, protection of intellectual property, development and licensing of technology and formation, incubation and investment in technology businesses. A wide range of technologies are commercialised within the areas of healthcare, energy, environment and emerging technology trends.


On 4 November 2010 Prime Minister David Cameron revealed in a speech given in East London that Imperial Innovations had agreed to advise on the creation of an accelerator space for spinout companies at the Queen Elizabeth Olympic Park as part of the new East London Tech City hub.[1]

Sources of Technology[edit]

In April 2005 Imperial Innovations entered into a 15-year agreement with Imperial College London to commercialise technology derived from research at Imperial. Imperial Innovations also commercialises technologies originating from outside Imperial College through incubation contracts with the Carbon Trust and Waste & Resources Action Programme and has commercialisation contracts with a number of multinational corporations including BAE Systems.

Spin-out companies[edit]

Imperial Innovations has established equity holdings in approximately 70 companies, the majority of which are spin-outs arising from technologies developed at Imperial College, and a high proportion of which are biotech or medical devices firms. The companies include: Econic Technologies, Ixico, Ionscope, and Equinox Pharma.Innovations has achieved some notable early successes with its investments. For example, in 2010, RespiVert, a small molecule drug discovery company, was sold to Centocor Ortho Biotech (now Janssen Biotech) resulting in the Group realising £9.5 million of gross cash proceeds from an investment of £2 million - See more at:


  1. ^ "East End tech city speech". Number 10. Retrieved 4 November 2010.